Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
Kura Oncology announced the publication of a manuscript in the journal Blood detailing the discovery and preclinical characterization of ziftomenib, a menin inhibitor approved in 2025 for relapsed or refractory NPM1-mutated AML. The study highlights ziftomenib’s differentiated binding profile and its ability to retain activity against certain treatment-emergent MEN1 mutations associated with resistance to other inhibitors.
Key figures
- Men1 mutation freq
- 1 of 29
- Menin dependent leukemia potential
- 50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.